This is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately.
|
|
- Hillary Elliott
- 8 years ago
- Views:
Transcription
1 REVISION OF THE CLINICAL TRIALS DIRECTIVE Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC. 2012/0192 (COD) Introduction This is a summary, prepared by Jim Murray, of some of the main features of the proposed regulation to revise the Clinical Trials Directive. I hope it is correct but I make no promises on that point. If any reader thinks I ve got it wrong anywhere please let me know that way I can try to improve this current version. This is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately. This note is published subject to a Creative Commons licence. If you pass it on, it would be nice of you to mention me. Background Most clinical trials are single country trials but multi country trials tend to be bigger and account for some 67% of patients in all trials in the EU (European Commission). The main purpose of the proposed regulation is to address the following criticisms by industry, academics and others: 1. The current application procedure for multi-country trials is too slow, complex and expensive in ways that do not add to the safety or efficacy of such trials. 2. The requirements for insurance or indemnification cover impose very high expenses and acts as a deterrent to clinical trials, especially but not only for academic researchers. 3. The current regime is does not distinguish between the different levels of risk for different clinical trials; low risk ( low intervention ) trials are subject to the same rules as others with higher levels of risk, and are therefore more expensive and cumbersome than they need to be.
2 Application for Authorisation of a Clinical Trial Under the regulation, there will be only one way to apply for authorisation for a clinical trial through a portal run by the European Commission. The Commission will not assess the application but all communication between the applicant and the member states where the trials will take place will pass back and forward through the portal one single application in one single dossier, shared by all the member states concerned. (Article 5 et al). On my reading of the proposal it also applies to single country trials, in other words to all clinical trials in the EEA without exception (Article 1). Assessment Part I One member state, probably the one suggested by the applicant, will take on the role of reporting member to prepare an assessment report on the scientific, therapeutic and safety aspects of the proposed trial. The other member states may submit opinions or queries to the reporting member state before the assessment is complete, but not after. When the assessment report is published, other member states may disagree with it but only on the specific grounds, set out in Article 8.2, and then only with a detailed justification in writing to be sent to the Commission, the other member states concerned and to the sponsor of the trial. (Article 6) Assessment Part II All member states where the trials will be conducted may carry out their own individual assessments on aspects of the trial that are governed by national laws, including informed consent, treatment of minors, liability for damages, recruitment of subjects and payment of investigators. (Article 7) Time Limits All stages of the process are subject to strict time limits. Reporting member states have ten days to say if an application is complete or not otherwise it is presumed to be complete. The reporting member state must complete the assessment report within ten days (for low intervention trials), 25 days (for ordinary trials) and 30 days (for advanced therapy trials). They may stop the clock to seek more
3 information but for no more than ten or twenty days depending on the type of trial. They may set deadlines for sponsors to reply to their questions and the application will be considered to be withdrawn if the sponsors do not reply on time. (Article 6) Member states must complete their (Part II) assessment within ten days. (Article 7.2) Modifications Clinical trials are sometimes changed while in progress. Under the regulation a new application will be necessary in such cases only where there is substantial modification a modification likely to have a substantial impact on the safety or rights of the subjects or on the reliability or robustness of the data generated in the clinical trial.(articles 16-24) Low Intervention Trials The regulation proposes a lighter regime for low intervention trials. These would be trials of medicines already authorised for use, used in the way for which they are authorised and with no more than minimal additional safety risks or burdens to patients in the monitoring and diagnostic process such as taking blood samples, for example. (Article 2.3) The time limits for approving low intervention trials are shorter than for other trials. Furthermore, the proposal does not require investigators and sponsors to have insurance or compensation schemes in place for low intervention trials on the grounds that standard professional liability insurance will provide sufficient coverage for such trials. (Article 72) Compensation Mechanisms For trials other than low intervention trials, member states are required to have in place national compensation mechanisms to ensure compensation under the national laws on legal liability if things go wrong. Coverage under these schemes should be free of charge for clinical trials that will not be used to obtain a marketing authorisation. In other cases, fees may be charged but on a not-for-profit basis. (Article 72-73)
4 Data The proposal contains a number of provisions on data. Clinical data submitted in support of an application should be based only on clinical trials recorded in a publicly accessible database. (Recital 20 et al) This provision would apply from the date the Regulation takes effect. Data from unregistered trials before that date could be included many relevant trials might have been carried out before registration was in place. Results of clinical trials should be reported to the competent authorities within one year of the completion of the trial unless a longer period was foreseen and approved at time of application. (Article 34.3) The Commission will set up a database that will include all the information passing through the portal. It will be publicly accessible, with exceptions for personal data, commercial confidentiality and law enforcement (i.e. data for the effective supervision of clinical trials by member states). (Articles 77-78) A summary of the results of each clinical trial should be placed on the EU database within one year of the completion of the trial. (Article 34.3) Sponsors must retain the Clinical Trial Master File, containing all details of the trial for five years. (Article 55) Administration Each member state must appoint a single contact point for the purposes of the regulation, to communicate through the portal with the reporting member state and the trial sponsor. A new EU advisory committee will be formed, made up of the members from the national contact points. (Articles 79-81) Member states are free to make their own arrangements for assessing applications, but the assessors must in each case be independent, without conflicts of interest and shall include a patient and someone whose primary interests are non-scientific. (Article 9) (Given the tight time scales, member states will have to have procedures in place to act quickly; otherwise they may just have to accept that a trial is authorised in their
5 country. Member states with complex authorisation procedures, perhaps involving different bodies, will have to adapt to the proposed regulation.) Safety Reporting Investigators shall report adverse events to the sponsor according to the terms of the particular protocol for a given trial.(article 37) Investigators must record all serious adverse effects during the trial and report them to the sponsor, unless the protocol says otherwise. (Article 37) Serious unexpected adverse effects must be reported immediately to a database set up by the European Medicines Agency. (Article 38) Unexpected events which affect the benefit-risk balance of the trial must be reported, without undue delay to all the relevant member states, through the portal. (In such cases urgent new safety measures may have to be taken and reported immediately.) (Article 50-51) Sponsors must report, within seven days, again through the portal, any serious breach of the regulation or the trial protocol. (Article 49) The sponsor must send to the EMA once a year a report on the safety of the medicines in the trial (apart from placebos and authorised medicines used according to their authorisation). (Article 39) For authorised medicines used according to their authorisation, any suspected serious adverse reactions should be reported once a year to the holder of the authorisation for that medicine (e.g. when a company is using a competitor s product in the trial). (Article 41) NB More specific requirements for safety reporting are set out in Annex III. Other Points There are many other provisions in the proposal that I have not covered here, including provisions on informed consent, contents of application dossiers, labelling, and (very important) trials outside the EU.
6 I think I have covered the main points, such as they are, relating to access to data and data disclosure. If you find anything I have overlooked on this point, please let me know. If you think there are other parts of the proposal that I should try to summarise, I m open to suggestions. Jim Murray 4 th October 2102.
Clinical trials regulation
Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update
More informationWhite Paper The EU Clinical Trials Regulation Main Changes and Challenges
White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationThe European Clinical Trials Framework Update on the Draft Clinical Trials Regulation
The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation Dr. Ilona Reischl BASG/AGES Austrian Agency for Health and Food Safety GmbH Content - References "Proposal for a Regulation
More informationResponse of the German Medical Association
Response of the German Medical Association to the European Commission proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationThe New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
More informationProposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EUROPEAN COMMISSION Brussels, 17.7.2012 COM(2012) 369 final 2012/0192 (COD) Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on clinical trials on medicinal products for human use,
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationThe New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
More informationLegal and governance framework
Annex A Legal and governance framework This annex is a brief guide to the legal and governance framework relevant to research in the UK. It is not intended to be a comprehensive statement of the law or
More informationDESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
More informationThe EU portal and database
The EU portal and database ECPC General Assembly - 20 June 2015 Presented by Laura Pioppo Clinical and Non-clinical Compliance Service An agency of the European Union Table of contents Legal basis CT programme
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationThe new European clinical trials regulation Dr. N.Gökbuget
The new European clinical trials regulation Dr. N.Gökbuget Head of Study Center Department of Medicine II and Goethe University Cancer Center Frankfurt, Germany European Leukemia Net: Major Aim to Foster
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationClinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation
Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation Joint BBS-EFSPI Seminar, Basel, 13 Nov 2014 Sabine Atzor, Head of EU Regulatory Policies PDR Overview
More informationFederated Access Management
Federated Access Management Document Version: 2 DRAFT Date: Oct 2011 Author (Version 2): Andrew Cormack (JANET(UK)) Authors (Version 1): Andrew Cormack (JANET(UK)), Eva Kassenaar (SURFnet), Mikael Linden
More informationHaving regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark Question 1: What laws or regulations apply to an application for conducting a clinical
More informationStrong support. Remaining concerns
EORTC opinion on the proposal for an EU Regulation on clinical trials on medicinal products for human use and the 7 th of June ENVI report on this proposal It is clear that the Commission and appointed
More informationQUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September
More informationAgence fédérale des médicaments et des produits de santé
Agence fédérale des médicaments et des produits de santé From Risk Management Plan to Risk Minimization Activities New Royal Decree: Status and General Explanation Role of the Pharmacovigilance Department
More informationRECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
More informationFederal agency for medicines and health products
Federal agency for medicines and health products A critical review of the proposed EU Clinical Trial regulation Walter Janssens Kristof Bonnarens April 2013 CT regulation - general Commission adopted the
More informationCLINICAL TRIAL LIABILITY INSURANCE
CLINICAL TRIAL LIABILITY INSURANCE - R.Qaiser, Faculty Member, NIA, Pune With the opening of insurance sector and the demise of tariff regime, suddenly the Competition has become very fierce and we are
More informationAct of 26 February 1998, containing rules on medical research involving human subjects (Medical Research (Human Subjects) Act)
[This is an unofficial translation and is provided for reference purposes only. It is not certified and it has not been authorised by the Dutch government; persons using this translation do so entirely
More informationEuropean Regulatory Newsletter July - September 2013
European Regulatory Newsletter July - September 2013 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree
More informationAdoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
More informationEFPIA position on Clinical Trials Regulation trialogue
EFPIA position on Clinical Trials Regulation trialogue As the revision of the Clinical Trial Directive enters the Trialogue phase, it is critical to remember that the key objective of this legislation
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationEnd of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
More informationREGULATION (EEC) No 2309/93
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health products and systems Medicinal products quality, safety and efficacy Brussels, 15 May 2013 sanco.ddg1.d.6(2013)1154216 THE RULES GOVERNING
More informationClinical Trial Compensation Guidelines
Clinical Trial Compensation Guidelines Preface These guidelines contain two distinct sections: Phase I Clinical Trials Compensation Guidelines Phases II, III and IV Clinical Trials Compensation Guidelines
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationEORTC position on the place for transparency in the clinical trials regulation
EORTC position on the place for transparency in the clinical trials regulation EORTC fully supports the need to increase transparency of clinical trials. Appropriate transparency within the clinical trials
More informationQuestions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
More informationCOLLECTIVE INVESTMENT LAW DIFC LAW No. 2 of 2010
---------------------------------------------------------------------------------------------- COLLECTIVE INVESTMENT LAW DIFC LAW No. 2 of 2010 ----------------------------------------------------------------------------------------------
More informationFederated Access Management
Federated Access Management Document Version: 10 DRAFT Date: Dec 2008 Authors: Andrew Cormack (JANET(UK)), Eva Kassenaar (formerly SURFnet), Mikael Linden (FUNET), Walter Martin Tveter (UNINETT), Abstract
More informationThe Electricity and Gas (Internal Markets) Regulations 2011
STATUTORY INSTRUMENTS 2011 No. 2704 ELECTRICITY GAS The Electricity and Gas (Internal Markets) Regulations 2011 Made - - - - 9th November 2011 Coming into force in accordance with regulation 1(1) 26.75
More informationReflection paper for laboratories that perform the analysis or evaluation of clinical trial samples
28 February 2012 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group Reflection paper for laboratories that perform the analysis or evaluation of clinical trial Draft agreed by GCP Inspectors Working
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationQuestions and Answers to the Annual Safety Report
Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit
More informationOfficial Gazette no. 213 of 14.9.2009 MINISTRY OF LABOUR, HEALTH AND SOCIAL POLICIES
The English version of this Decree was prepared in order to help comprehension by non- Italian mother tongue users, but it is NOT an official document. Please, refer to the Italian version for the only
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationEFPIA Principles for the Development of the EU Clinical Trials Portal and Database
Position Paper EFPIA Principles for the Development of the EU Clinical Trials Portal and Database Executive summary EFPIA sees the implementation of the Clinical Trials Regulation 1 as an opportunity to
More informationHow to search the EU Clinical Trials Register
28 April 2014 Information and Communications Technology Contents Contents... 1 1. Searching the EU Clinical Trials Register... 1 1.1. Basic search... 2 1.2. Search for multiple words (AND operator)...
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationMontelukast 10mg film-coated tablets PL 17907/0474
Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page
More informationLEBANESE MINISTRY OF HEALTH DIRECTIVE
LEBANESE MINISTRY OF HEALTH DIRECTIVE LAYING DOWN DETAILED GUIDELINES FOR SPONSORS OF CLINICAL TRIALS March 2012 Field of Application General Considerations Trial s submission Validity of the F-MRI opinion
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
More informationThe potential legal consequences of a personal data breach
The potential legal consequences of a personal data breach Tue Goldschmieding, Partner 16 April 2015 The potential legal consequences of a personal data breach 15 April 2015 Contents 1. Definitions 2.
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationBRIEFING. 3 November 2006
Avenue Louise 240, Box 5 1050 Brussels Telephone: 32 (0)2 626 05 00 Fax: 32 (0)2 626 05 10 www.steptoe.com E-Mail: pwoolfson@steptoe.com BRIEFING Re: Delay in harmonising policyholder protection/insurance
More informationPost-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More information20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
More informationResearch Governance Framework for Health and Social Care
Research Governance Framework for Health and Social Care Second edition, 2005 Research Governance Framework for Health and Social Care Foreword The Research Governance Framework outlines principles of
More informationOperational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
More informationCompetentes en Medicamentos
VIII Encuentro de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (EAMI) 12-14 de Mayo 2010 Madrid MARTIN TERBERGER Jefe de la Unidad de Productos Farmacéuticos Nuevas iniciativas
More informationDisability Discrimination Act 2005
Disability Discrimination Act 2005 CHAPTER 13 Explanatory Notes have been produced to assist in the understanding of this Act and are available separately 7 50 Disability Discrimination Act 2005 CHAPTER
More informationEDUCATION AND ADOPTION BILL EXPLANATORY NOTES
EDUCATION AND ADOPTION BILL EXPLANATORY NOTES What these notes do. These Explanatory Notes have been prepared by the Department for Education in order to assist the reader of the Bill and to help inform
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationGuidance notes on collection of drug safety information by employees and agents of pharmaceutical companies
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of
More informationEnergy Act 2013 CHAPTER 32. Explanatory Notes have been produced to assist in the understanding of this Act and are available separately
Energy Act 2013 CHAPTER 32 Explanatory Notes have been produced to assist in the understanding of this Act and are available separately Energy Act 2013 CHAPTER 32 CONTENTS PART 1 DECARBONISATION 1 Decarbonisation
More informationVersion history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
More informationVOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. June 2013
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Revision 4 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING
More informationTEMPLATE DATA MANAGEMENT PLAN
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
More informationUC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review Cindy Gates IRB Administration Tips for Reviewer s Comments - Comments should be easily transferrable
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Norway
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Norway Question 1: What laws or regulations apply to an application for conducting a clinical
More informationInsurance Policy for Clinical Trials
Insurance Policy for Clinical Trials Carlo Tomino Pharm.D. Mwanza, June 2012 Ministry of Labour, of Health and Social Policies Minimum requirement for the insurance policies to protect participants to
More informationSETTING UP INTERNATIONAL CLINICAL TRIALS IN EUROPE: THE EORTC EXPERIENCE
SETTING UP INTERNATIONAL CLINICAL TRIALS IN EUROPE: THE EORTC EXPERIENCE Dr. Pharm. Fabienne LAMBERT, PhD Head Regulatory Affairs Unit European Organisation for Research and Treatment of Cancer (EORTC)
More informationQueensland can get on with the job
The department s red tape reduction programs have made it easier and less costly for Queenslanders to get on with the job and do business in the State. Red tape reduction programs are also contributing
More informationMedicines for Human Use (Clinical Trials Regulations) 2004. Informed consent in clinical trials
Medicines for Human Use (Clinical Trials Regulations) 2004 Informed consent in clinical trials Introduction 1. This information note summarises the statutory requirements for informed consent of participants
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationAuthorisation and Restriction Newsletter
Authorisation and Restriction Newsletter August 2010, N 1 The information contained in this document is intended for guidance only and whilst the information is provided in utmost good faith and has been
More informationThe reform of the EU Data Protection framework - Building trust in a digital and global world. 9/10 October 2012
The reform of the EU Data Protection framework - Building trust in a digital and global world 9/10 October 2012 Questionnaire addressed to national Parliaments Please, find attached a number of questions
More informationProfessional Standards and Guidelines
College of Physicians and Surgeons of British Columbia Professional Standards and Guidelines Conflict of Interest Arising from Clinical Research Preamble This document is a guideline of the Board of the
More informationNSW Cancer Trials Network Network Portfolio Policy October 2012
NSW Cancer Trials Network Network Portfolio Policy October 2012 E12/18446 Cancer Institute NSW Page 1 of 7 Contents BACKGROUND... 3 NSW CANCER TRIALS NETWORK PORTFOLIO KEY PRINCIPLES... 3 PORTFOLIO COMPLIANCE
More informationGuidance to Research Ethics Committees on Initial Facility Assessment
Guidance to Research Ethics Committees on Initial Facility Assessment Introduction One of the roles of a Research Ethics Committee is to provide an opinion on a proposed study, based on the suitability
More information(Legislative acts) DIRECTIVES
1.7.2011 Official Journal of the European Union L 174/1 I (Legislative acts) DIRECTIVES DIRECTIVE 2011/61/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 8 June 2011 on Alternative Investment Fund
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationVOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/BL D(2002) NOTICE TO APPLICANTS Revision 3 VOLUME 2A Procedures for marketing authorisation CHAPTER 1
More informationFinancial Services Act 2010
Financial Services Act 2010 CHAPTER 28 CONTENTS Objectives of FSA etc 1 Financial stability objective 2 Enhancing public understanding of financial matters etc 3 Meeting FSA s regulatory objectives Remuneration
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationClinical Trials. Clinical trials the basics
Clinical Trials Clinical Trials This brochure is for people making decisions about cancer treatment. You may be thinking about a clinical trial for you or your child but need to know more before you decide.
More informationSUMMARY OF THE IMPACT ASSESSMENT
EN EN EN EUROPEAN COMMISSION Brussels, 12.7.2010 SEC(2010) 846 COMMISSION STAFF WORKING DOCUMENT SUMMARY OF THE IMPACT ASSESSMENT Accompanying document to the Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT
More information